450 Brookline Avenue, Boston, MA, 02115 · (617) 632-3000
Beds
30
FY 2025
Star rating
Not rated
Overall rating
Net patient revenue
$3.01B
FY 2025
Net income
$335.5M
Patient care margin -26.8%
Discharges
1,295
Occupancy 97.3%
Clinicians
1,347
Medicare clinicians who work here
From the hospital's yearly cost reports (fiscal years as the hospital reports them)
Locations are shown at the center of the ZIP code.
US dollars as reported. Patient care margin = net patient revenue minus operating expenses, before other income such as grants, donations and investments.
| Fiscal year | Net patient revenue | Operating expenses | Patient care margin | Net income | Discharges | Uncompensated care | Medicare days | Medicaid days |
|---|---|---|---|---|---|---|---|---|
| 2025 | $3.01B | $3.82B | -26.8% | $335.5M | 1,295 | - | 35.0% | 2.2% |
Medicare clinicians who list this hospital, by specialty
Hospital outpatient services by payment group (APC), 2024
| Service group | Services | Patients | Medicare pays per service | All hospitals |
|---|---|---|---|---|
| APC 5073 Level 3 Excision/ Biopsy/ Incision and Drainage | 1,353 | 1,060 | $2,421.26 | $2,141.49 |
| APC 5182 Level 2 Vascular Procedures | 44 | 44 | $1,370.39 | $1,204.32 |
| APC 5072 Level 2 Excision/ Biopsy/ Incision and Drainage |
Official US government data: hospital records, ownership records, yearly cost reports and quality measures, linked by the hospital's CCN and NPI. Financials are for fiscal years as reported by the hospital.
| 2024 | $2.59B | $3.35B | -29.2% | $256.7M | 1,299 | - | 34.0% | 1.4% |
| 2023 | $2.26B | $2.99B | -32.4% | $407.9M | 1,300 | - | 33.2% | 2.0% |
| 2022 | $1.88B | $2.54B | -35.1% | -$11.8M | 1,290 | - | 35.1% | 1.6% |
| 2021 | $1.56B | $2.21B | -41.4% | $326.0M | 1,431 | - | 35.3% | 3.7% |
| 2020 | $1.28B | $1.95B | -51.8% | $50.8M | 1,420 | $17K | 36.1% | 2.1% |
| 40 |
| 38 |
| $1,387.30 |
| $1,219.56 |
| APC 5244 Level 4 Blood Product Exchange and Related Services | 29 | 29 | $56,849.60 | $56,849.60 |
| APC 5165 Level 5 ENT Procedures | - | - | - | $4,436.36 |
| APC 5163 Level 3 ENT Procedures | - | - | - | $1,105.91 |
| APC 5341 Level 1 Abdominal/Peritoneal/Biliary and Related Procedures | - | - | - | $2,635.67 |
| APC 5414 Level 4 Gynecologic Procedures | - | - | - | $2,389.24 |
| APC 5627 Level 7 Radiation Therapy | - | - | - | $6,120.75 |
| APC 5164 Level 4 ENT Procedures | - | - | - | $2,217.17 |
| APC 8011 Comprehensive Observation Services | - | - | - | $2,090.36 |
Reported payments to this teaching hospital
| Company | Payments | Amount |
|---|---|---|
| Genentech, Inc. ROG.SW | 52 | $46.1M |
| Abbvie Inc. ABBV | 75 | $12.1M |
| AstraZeneca Pharmaceuticals LP AZN | 40 | $9.7M |
| Pfizer Inc. PFE | 113 | $9.5M |
| Merck Sharp & Dohme LLC MRK | 32 | $8.3M |
| Celgene Corporation BMY | 36 | $8.2M |
| Daiichi Sankyo Inc. 4568.T | 748 | $5.4M |
| E.R. Squibb & Sons, L.L.C. BMY | 85 | $5.3M |
| Novartis Pharmaceuticals Corporation NVS | 37 | $4.7M |
| Amgen Inc. AMGN | 12 | $4.5M |
Official US government data on Original Medicare hospital stays and outpatient services; groups with fewer than 11 cases are not published. Payments are those drug and device companies must report.
Dana-Farber Cancer Institute is a nonprofit short-term acute care hospital in Boston, MA with 30 beds, part of Mass General Brigham.
Dana-Farber Cancer Institute in Boston, MA has 30 beds (fiscal year 2025 cost report); 27 beds are certified for Medicare. It discharged 1,295 inpatients that year, with 97.3% of its beds in use on average.
In fiscal year 2025 (ending 2025-09-30), Dana-Farber Cancer Institute reported net patient revenue of $3.01B and operating expenses of $3.82B, a margin on patient care of -26.8%. After other income and expenses its net income was $335.5M (8.1% of revenue), so it made a profit that year.
Dana-Farber Cancer Institute is part of Mass General Brigham, a health system with 15 hospitals based in Somerville, MA. It is a nonprofit hospital.
Dana-Farber Cancer Institute has no overall star rating, usually because it reports too few quality measures (for example small, specialty or federal hospitals).
Emergency services are not reported for Dana-Farber Cancer Institute.
1,347 Medicare clinicians list Dana-Farber Cancer Institute as a hospital they work at, most often in Medical Oncology, Diagnostic Radiology, Pathology.
In 2025, companies reported $140.1M in payments to Dana-Farber Cancer Institute as a teaching hospital ($63.1M general and $77.1M for research) from 80 companies.